CAR T-Cell Therapy - Microscopic T-Cell Cancer Target
CAR T-CELL THERAPY IN THE USA

CAR T-Cell Therapy.A New Way to Fight Cancer.

Explore leading U.S. CAR T-cell programs for eligible blood cancers, with physician-led guidance to identify the right specialists, centers, and treatment pathways.

Uses Your Own
Immune Cells
Precision Cancer
Targeting
FDA-Approved
Treatment
Personalized for
Every Patient

Advanced Immunotherapy

Helping eligible patients access leading CAR T-Cell programs at renowned U.S. cancer centers.

HOW CAR T-CELL THERAPY WORKS

CAR T-Cell Therapy:
Your Immune Cells,
Reengineered to Fight Cancer.

CAR T-cell therapy is a form of cancer immunotherapy that modifies a patient's own T cells to recognize specific targets on cancer cells. The engineered cells are expanded and returned to the patient, where they can identify and attack targeted cancer cells.

Currently used primarily for certain blood cancers, CAR T-cell therapy is also being studied for additional cancers through clinical trials.

Microscopic view of CAR T-cell attacking cancer cells

Uses Your Own
Immune Cells

Personalized from your blood

Engineered to
Recognize Cancer

Targets specific cancer cells

Expanded &
Reinfused

Millions of cells grown in a lab

Designed to
Attack Cancer

Seeks out and destroys targeted cancer cells

WHICH CANCERS CAN CAR T-CELL THERAPY TREAT?

Could CAR T-Cell Therapy
Be an Option for Your Cancer?

CAR T-cell therapies are approved for several blood cancers, while new CAR-T approaches are being investigated through clinical trials.

Certain Lymphomas

Certain Lymphomas

DLBCL • Follicular lymphoma • Mantle cell lymphoma • Other eligible B-cell lymphomas

Multiple Myeloma

Multiple Myeloma

BCMA-targeted CAR-T options for selected patients.

Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

CAR-T options for eligible B-cell ALL patients.

Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

CAR-T options may be available for selected patients.

Solid Tumors — Clinical Trials

Solid Tumors — Clinical Trials

Investigational CAR-T approaches are being studied for selected solid tumors.

Eligibility depends on your diagnosis, prior treatments, and individual evaluation.
Our team will help you explore the right options.

FINDING THE RIGHT CAR-T PROGRAM

The Right CAR-T Pathway
Starts With the Right Match.

Your diagnosis, biomarkers, prior treatments and disease status help determine which CAR-T options and U.S. programs may be relevant to your case.

01

DIAGNOSIS

We review your diagnosis and treatment history in detail.

02

MEDICAL & MOLECULAR REVIEW

Our experts evaluate your records, biomarkers, and prior therapies.

03

CAR-T ELIGIBILITY

We determine potential eligibility for approved CAR-T therapies or clinical trials.

04

U.S. PROGRAM / CLINICAL TRIAL MATCH

We identify the most appropriate U.S. CAR-T programs and specialists for your case.

05

ACCESS & COORDINATION

We handle appointments, records, travel support, and ongoing care coordination.

Not just a search. A case-specific pathway to the right U.S. CAR-T options.
Secure • Confidential • No obligation to proceed

How CAR T-Cell Therapy Is Made

Your T cells are collected, engineered, expanded, and returned to your body.

1

Collection

From your blood

T cells are collected from your blood through a process called leukapheresis.

Collection
2

Engineering

Reprogrammed to find and fight cancer

T cells are genetically modified in a lab to add a CAR (chimeric antigen receptor) that helps them recognize cancer cells.

Engineering
3

Expansion

Grown into millions of warriors

Engineered T cells are multiplied in the lab to create millions of CAR T cells ready for infusion.

Expansion
4

Infusion

Back to you

The engineered CAR T cells are infused back into your body, where they can find and attack cancer cells.

Infusion

Each CAR T-cell therapy is unique and may take several weeks from cell collection to infusion. Our team will guide and support you at every step.

ACCESS LEADING U.S. CAR-T PROGRAMS

World-Class CAR-T Expertise.
One Coordinated Path.

MediPocket helps patients navigate appropriate CAR-T programs across leading U.S. cancer centers based on diagnosis and eligibility.

LEADING U.S. CAR-T PROGRAMS WE NAVIGATE
MD Anderson Cancer Center
Memorial Sloan Kettering
Mayo Clinic
Dana-Farber Cancer Institute
Johns Hopkins Medicine
Stanford Medicine
UCLA Health

MediPocket is an independent care navigation company. We are not owned or operated by any of the hospitals listed above. Our team helps you navigate and access the right programs for your unique case.

Expert guidance
Unbiased navigation
Access to leading U.S. programs
TWO PATHWAYS. ONE MISSION.

Approved or Investigational,
We'll Help You Find What's Right.

Whether an FDA-approved therapy or a clinical trial is the right path, MediPocket helps you explore every appropriate option.

FDA-ApprovedCAR-T

Established CAR-T therapies are available for eligible patients with certain leukemias, lymphomas and multiple myeloma.

FDA-Approved CAR-T cells under microscope
InvestigationalCAR-T Trials

Research is expanding CAR-T into new targets, earlier treatment settings and selected solid tumors.

Investigational CAR-T clinical trials cells under microscope

Our team evaluates your case to determine the most appropriate pathway for your diagnosis and goals.

WHY MEDIPOCKET

Why Patients Choose MediPocket

We make complex care simpler—connecting you to the right CAR-T experts, programs and support in the U.S.

01

Physician-Led Case Review

Your diagnosis and treatment history guide the search.

02

U.S. Program Matching

We identify relevant specialists, centers and research pathways.

03

Cross-Border Coordination

Records, appointments, medical visa support and travel coordination.

04

One Dedicated Care Navigator

One point of coordination throughout your U.S. care journey.

Expert Guidance
Personalized Matching
End-to-End Support
PATIENT STORIES

When the Right Treatment
Changes What's Possible.

Real patients. Real journeys. Coordinated care that opens new possibilities.

MediPocket helped us understand every option and connected us to a leading CAR-T program in the U.S. The care our son received gave us hope—and a future.

M. S.|
UAE
UAE
DiagnosisAcute Lymphoblastic Leukemia (ALL)
ServiceCAR-T Navigation & Coordination

After years of treatments that stopped working, CAR-T changed everything. MediPocket made the complex process simple and stress-free.

R. K.|
India
India
DiagnosisDiffuse Large B-Cell Lymphoma
ServiceCAR-T Navigation & Coordination

We explored clinical trials when approved options were not available. MediPocket found the right trial at the right time for my father.

A. H.|
Saudi Arabia
Saudi Arabia
DiagnosisMultiple Myeloma
ServiceCAR-T Clinical Trials Matching

From records and appointments to travel and stay, MediPocket coordinated everything seamlessly. We could focus on what mattered most—her recovery.

L. P.|
Kenya
Kenya
DiagnosisFollicular Lymphoma
ServiceCAR-T Navigation & Coordination

The MediPocket team was with us at every step. Their guidance helped us find the right specialists and the right treatment for my husband.

S. T.|
Qatar
Qatar
DiagnosisMantle Cell Lymphoma
ServiceCAR-T Navigation & Coordination
Patient names are represented by initials to protect privacy.
FAQ

CAR T-Cell Therapy FAQs

Answers to the most important questions patients and families ask when considering CAR-T treatment in the U.S.

Patients with certain relapsed or refractory blood cancers—such as lymphomas, leukemias, and multiple myeloma—who have undergone at least two prior lines of standard therapy are typically eligible. Eligibility depends on cancer type, prior treatments, and current physical health status.
CAR T-cell therapies are FDA-approved for several types of blood cancers, including certain non-Hodgkin lymphomas (like DLBCL), Acute Lymphoblastic Leukemia (ALL), and Multiple Myeloma. Clinical trials are currently exploring CAR-T for solid tumors and other types of leukemia.
Yes. International patients can access leading U.S. cancer centers for CAR-T. MediPocket handles the complete pathway, including clinical matching, medical records coordination, appointment scheduling, and travel logistics.
If FDA-approved options are not suitable, you may be eligible for investigational CAR T-cell therapies via U.S. clinical trials. Clinical trials test new CAR-T designs, target antigens, and therapeutic settings.
Yes. Hundreds of clinical trials are active across leading U.S. cancer centers, investigating CAR-T for solid tumors, earlier lines of treatment, and next-generation designs that reduce side effects.
The complete process typically takes several weeks. It includes initial collection (leukapheresis), 2 to 4 weeks of laboratory cell engineering, and a brief hospital stay (7-14 days) for chemotherapy preparation and cell infusion.
To initiate a review, we require your recent biopsy/pathology reports, imaging scans (PET/CT), summaries of prior treatments (chemo/radiation), current blood counts, and your oncologist's case summary.
CAR T-cell therapy is a highly specialized treatment. The cost includes laboratory manufacturing, hospital stays, and medical management. MediPocket helps you evaluate program costs and navigation options.
No. MediPocket is an independent care navigation company. We do not provide treatment ourselves. Instead, we connect patients directly with leading specialists and FDA-approved programs at top U.S. cancer centers.
We provide complete cross-border care navigation: matching your case to top programs, managing records, helping with medical visa support, coordinating appointments, and supplying a care navigator at every stage.

Still Have Questions?

Our team is here to provide clarity and help you understand your best next steps.

Confidential. Physician-Reviewed. No Obligation.
Patient Couple receiving clinical guidance
START YOUR CAR-T CASE REVIEW

Could CAR-T Be the
Right Next Step?

Every case is different. Share your diagnosis and treatment history, and our team will help identify relevant U.S. CAR-T programs and clinical trial pathways to explore.

Physician-Led Review
Confidential
U.S. Program Navigation

REQUEST A CAR-T CASE REVIEW

Tell us about your case. We'll help you understand what options may be worth exploring.

Upload Medical Records (Optional)PDF, JPG, PNG up to 20MB
Confidential inquiry • No obligation to proceed

CAR-T eligibility and treatment decisions are determined by the treating institution and clinical team. MediPocket provides independent care navigation and coordination and does not provide CAR-T treatment.

WhatsApp us